These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1855752)

  • 1. [Using activated macrophages for tumor therapy? Priv.-Doz. Dr. R. Andreesen presents new perspectives in cancer research. Interview by Elisabeth B. Moosmann].
    Andreesen R
    Fortschr Med; 1991 Apr; 109(12):21-2. PubMed ID: 1855752
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune control of neoplasia by adoptive transfer of macrophages: potentiality for antigen presentation and gene transfer.
    Bartholeyns J; Lopez M
    Anticancer Res; 1994; 14(6B):2673-6. PubMed ID: 7872699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results.
    Bartholeyns J; Lopez M; Andreesen R
    Anticancer Res; 1991; 11(3):1201-4. PubMed ID: 1888150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives for antitumor therapy based on the recognition mechanism by which macrophages identify undesirable foreign and native cells and molecules.
    Takiguchi K; Inagawa H; Nishizawa T; Kohchi C; Soma G
    Anticancer Res; 2002; 22(6C):4277-80. PubMed ID: 12553069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
    Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
    Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune therapy with macrophages: present status and critical requirements for implementation.
    Bartoleyns J; Romet-Lemonne JL; Chokri M; Lopez M
    Immunobiology; 1996 Oct; 195(4-5):550-62. PubMed ID: 8933156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon-gamma.
    Lei H; Ju DW; Yu Y; Tao Q; Chen G; Gu S; Hamada H; Cao X
    Gene Ther; 2000 Apr; 7(8):707-13. PubMed ID: 10800095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of macrophages in anticancer therapy: the macrophage network theory.
    Kohchi C; Inagawa H; Hino M; Oda M; Nakata K; Yoshida A; Hori H; Terada H; Makino K; Takiguchi K; Soma G
    Anticancer Res; 2004; 24(5C):3311-20. PubMed ID: 15515426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
    Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
    Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New in vitro test systems].
    Hofstädter F; Konur A; Andreesen R; Knüchel R
    Urologe A; 1995 May; 34(3):212-4. PubMed ID: 7610515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cell therapy in solid tumors].
    Ravaud A
    Bull Cancer; 2001 Jan; 88(1):91-100. PubMed ID: 11182658
    [No Abstract]   [Full Text] [Related]  

  • 12. Antitumoral effects of lipopolysaccharides, tumor necrosis factor, interferon and activated macrophages: synergism and tissue distribution.
    Chokri M; Freudenberg M; Galanos C; Poindron P; Bartholeyns J
    Anticancer Res; 1989; 9(4):1185-90. PubMed ID: 2817800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immuno-cell therapy of cancer in Japan.
    Egawa K
    Anticancer Res; 2004; 24(5C):3321-6. PubMed ID: 15515427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive cellular immunotherapy of cancer.
    Winter H; Fox BA
    Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation.
    Mantovani A; Sica A; Allavena P; Garlanda C; Locati M
    Hum Immunol; 2009 May; 70(5):325-30. PubMed ID: 19236898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approach to the adoptive immunotherapy of Walker-256 carcinosarcoma with activated macrophages combined with photodynamic therapy.
    Dima VF; Ionescu MD; Balotescu C; Dima SV; Vasiliu V; Lacky D
    Roum Arch Microbiol Immunol; 2001; 60(3):237-56. PubMed ID: 12165976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis of macrophages: a potential way to identify novel proteins associated with activation of macrophages for tumor cell killing.
    Zhang L; Zhu H; Lun Y; Yan D; Yu L; Du B; Zhu X
    Cell Mol Immunol; 2007 Oct; 4(5):359-67. PubMed ID: 17976316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor tissue recycling--a new combination treatment for solid tumors: experimental and preliminary clinical research.
    Li B; Ding J; Larson A; Song S
    In Vivo; 1999; 13(5):433-8. PubMed ID: 10654199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of lymphokine-induced macrophage activation by tumor necrosis factor-alpha.
    Heidenreich S; Weyers M; Gong JH; Sprenger H; Nain M; Gemsa D
    J Immunol; 1988 Mar; 140(5):1511-8. PubMed ID: 3126228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly I:C activated macrophages are tumoricidal for TNF-alpha-resistant 3LL tumor cells.
    Remels L; Fransen L; Huygen K; De Baetselier P
    J Immunol; 1990 Jun; 144(11):4477-86. PubMed ID: 2111350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.